30日間連続 1ch 心電図ホルター又は二週間連続モニター用設定可 FDA認可済 本邦研究用

30日間連続 1ch 心電図ホルター又は二週間連続モニター用設定可 FDA認可済 本邦研究用

体温センサー 0.1°精度 72時間 ディスポ スマホ・タブレット連携 FDA認可 本邦研究用

体温センサー 0.1°精度 72時間 ディスポ スマホ・タブレット連携 FDA認可 本邦研究用

2009年11月3日火曜日

6分歩行が、心臓人工弁術後予後に有効

Preoperative 6 Minute Walk Test Adds Prognostic Information to Euroscore in Patients Undergoing Aortic Valve Replacement

Abstract
Aims: We investigated the additive prognostic value of the 6MWT to Euroscore in patients with severe aortic stenosis undergoing aortic valve replacement (AVR).
Methods and results: 208 patients with severe AS underwent six minute walk test (6MWT) prior to aortic valve replacement (AVR), as part of a randomized trial (ASSERT) comparing stented and stentless aortic valves.
Clinical follow-up was available for 200 patients up to 12 months. The rate of death, myocardial infarction (MI) or stroke (time to first event) was 13% (n=14) in patients walking <300 m compared to 4% (n=4) in those who walked 300 m (p= 0.017). When rate of death, MI or stroke by Euroscore risk was stratified by 6 minute walking distance, the 6MWT added prognostic information. In a Cox regression analysis 6MWT distance was the only variable retained as an independent predictor of the composite outcome of death, MI or stroke at 12 months (HR 0.28 95% CI 0.09-0.85, p=0.025). Conclusions: The 6MWT is safe and feasible to carry out in patients with severe aortic stenosis prior to AVR, and provides potentially important functional and prognostic information to clinical assessment and the Euroscore risk score

0 件のコメント:

コメントを投稿